Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Trillium Looks To Lead The Immuno-Oncology Pack In CD47 Inhibition

Executive Summary

Emerging Company Profile: Toronto biotech thinks it will differentiate from the current IO paradigm with CD47 inhibition, and from competitors in its space by directly targeting a receptor found in the tumor microenvironment.

Advertisement

Related Content

Science Matters: CD47 Pathway Links To CV Disease, New Drug Development Opportunities
Forty Seven Raises $75 Million For Possible 'Universal' Cancer Therapy

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register